<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04906824</url>
  </required_header>
  <id_info>
    <org_study_id>GLRA-G011</org_study_id>
    <nct_id>NCT04906824</nct_id>
  </id_info>
  <brief_title>Post-Market Registry in Europe and US for the Use of VascuCelTM</brief_title>
  <acronym>VascuCel</acronym>
  <official_title>Post-Market Registry in Europe and US for the Use of VascuCelTM</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Admedus Regen Pty Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Avania</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Admedus Regen Pty Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a post-market, multi-centre, open-label registry designed to collect prospective&#xD;
      safety and performance data on the use of VascuCel in patients who require great vessel&#xD;
      reconstruction, peripheral vascular reconstruction or suture line buttressing. This registry&#xD;
      will collect safety and performance data up to 2 years following implantation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Post-market, prospective, multi-centre, open-label, registry designed to collect prospective&#xD;
      safety and performance data on the use of VascuCel in patients with vascular disorders and in&#xD;
      accordance with local standard of care. The Registry has been designed to collect data up to&#xD;
      2 years following implantation. The VascuCel Registry will collect data on the use of the&#xD;
      VascuCel, for the following major indications:&#xD;
&#xD;
        -  Great vessel reconstruction&#xD;
&#xD;
        -  Peripheral vascular reconstruction&#xD;
&#xD;
      As suture line buttressing is a procedure that does not consistently use tissue, data on this&#xD;
      indication will only be included if available. Data will be prospectively collected by the&#xD;
      sites on registry-specific electronic case report forms (eCRFs). The primary endpoints will&#xD;
      assess device's safety and performance through measures and images obtained via the&#xD;
      facility's standard of care at the respective registry site. Additional data will also be&#xD;
      collected from the implant procedure to assess user (surgeon) satisfaction with the devices'&#xD;
      handling and performance.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2021</start_date>
  <completion_date type="Anticipated">September 2025</completion_date>
  <primary_completion_date type="Anticipated">October 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of graft related reintervention</measure>
    <time_frame>30 days post procedure.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of patch related morbidity</measure>
    <time_frame>30 days post procedure.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of graft related reintervention</measure>
    <time_frame>at 1 and 2 years post procedure.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rates of restenosis</measure>
    <time_frame>at 30 days and 1 and 2 years follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rates of measurement of the dynamic flow by facility standard of care â‰¥110-175* cm/sec for peripheral vascular location</measure>
    <time_frame>at 30 days and 1 and 2 years follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>incidence of Patch dehiscence</measure>
    <time_frame>at 30 days and 1 and 2 years follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>incidence of Patch calcification</measure>
    <time_frame>at 30 days and 1 and 2 years follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>incidence of Patch retraction</measure>
    <time_frame>at 30 days and 1 and 2 years follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>incidence of unanticipated and rare events</measure>
    <time_frame>at 30 days and 1 and 2 years follow-up</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Great Vessel Reconstruction</condition>
  <condition>Peripheral Vessel Reconstruction</condition>
  <condition>Suture Line Buttressing</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>great vessel reconstruction; peripheral vascular reconstruction; suture line buttressing</intervention_name>
    <description>VascuCel implantation in order to perform great vessel reconstruction; peripheral vascular reconstruction; suture line buttressing</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        VascuCel is indicated for the repair of vascular defects including great vessel&#xD;
        reconstruction, peripheral vascular reconstruction and suture line buttressing.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  patient has signed the informed consent&#xD;
&#xD;
          -  patient is a candidate for treatment with VascuCel per approved device indications.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  no study specific exclusion criteria; patients treated per standard clinical practice&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Ioana Ghiu</last_name>
    <role>Study Director</role>
    <affiliation>Anteris</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jurriaan Sombeek</last_name>
    <phone>+31 30 229 2727</phone>
    <phone_ext>509</phone_ext>
    <email>jurriaan.sombeek@avaniaclinical.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ioana Ghiu</last_name>
    <phone>001 612 219 6032</phone>
    <email>ighiu@anteristech.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>ASST Sette Laghi Varese</name>
      <address>
        <city>Varese</city>
        <zip>21100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Gabriele Piffaretti, Prof</last_name>
      <email>gabriele.piffaretti@uninsubria.it</email>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>May 25, 2021</study_first_submitted>
  <study_first_submitted_qc>May 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 28, 2021</study_first_posted>
  <last_update_submitted>May 25, 2021</last_update_submitted>
  <last_update_submitted_qc>May 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

